2VXD image
Deposition Date 2008-07-03
Release Date 2008-07-15
Last Version Date 2024-05-15
Entry Detail
PDB ID:
2VXD
Keywords:
Title:
The structure of the C-terminal domain of Nucleophosmin
Biological Source:
Source Organism:
HOMO SAPIENS (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
150
Conformers Submitted:
20
Selection Criteria:
LEAST RESTRAINT VIOLATION
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:NUCLEOPHOSMIN
Gene (Uniprot):NPM1
Chain IDs:A
Chain Length:54
Number of Molecules:1
Biological Source:HOMO SAPIENS
Ligand Molecules
Primary Citation
Structural Consequences of Nucleophosmin Mutations in Acute Myeloid Leukemia.
J.Biol.Chem. 283 23326 ? (2008)
PMID: 18511415 DOI: 10.1074/JBC.M801706200

Abstact

Mutations affecting NPM1 (nucleophosmin) are the most common genetic lesions found in acute myeloid leukemia (AML). NPM1 is one of the most abundant proteins found in the nucleolus and has links to the MDM2/p53 tumor suppressor pathway. A distinctive feature of NPM1 mutants in AML is their aberrant localization to the cytoplasm of leukemic cells. This mutant phenotype is the result of the substitution of several C-terminal residues, including one or two conserved tryptophan residues, with a leucine-rich nuclear export signal. The exact molecular mechanism underlying the loss of nucleolar retention, and the role of the tryptophans, remains unknown. In this study we have determined the structure of an independently folded globular domain in the C terminus of NPM1 using NMR spectroscopy, and we report that the conserved tryptophans are critical for structure. This domain is necessary for the nucleolar targeting of NPM1 and is disrupted by mutations in AML with cytoplasmic NPM1. Furthermore, we identify conserved surface-exposed lysine residues that are functionally rather than structurally important for nucleolar localization. This study provides new focus for efforts to understand the pathogenesis of AML with cytoplasmic NPM1 and may be used to aid the design of small molecules that target the C-terminal domain of NPM1 to act as novel anti-proliferative and anti-leukemia therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures